Simparo has filed a notice of an exempt offering of securities to raise $3 Million in New Funding.
According to filings with the U.S. Securities and Exchange Commission, Simparo is raising up to $3,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Simparo
Simparo Surgical is a medical device company specializing in innovative solutions for thumb carpometacarpal (CMC) joint reconstruction, particularly for arthritis. The company’s flagship product is the Anchor Line Fixation System, which utilizes patented Falcon Suture Clutch technology to simplify CMC Suspensionplasty procedures. This system offers advantages such as secure titanium anchor fixation, no bone tunnels or tendon harvesting, and a single incision, aiming to reduce surgical time and enhance patient satisfaction. Simparo’s approach is designed to provide a stable, reproducible repair with bone-to-bone fixation of a suture suspension sling, building upon the clinical success of Suture Suspension Arthroplasty. The Falcon Suture Clutch, a proprietary cinching and tensioning device, allows surgeons to easily apply and lock tension, leading to a more anatomic reconstruction and potentially faster patient recovery.
To learn more about Simparo, visit https://www.simparosurgical.com/
Simparo Linkedin Page: https://www.linkedin.com/company/simparo-surgical/
Contact:
James Harber, Chief Executive Officer
251-301-7931
https://www.linkedin.com/in/charber/
SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.
